ivacaftor / lumacaftor

Known as: IVACAFTOR/LUMACAFTOR, ivacaftor and lumacaftor, ivacaftor, lumacaftor drug combination 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
051020152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND The 24-week safety and efficacy of lumacaftor/ivacaftor combination therapy was shown in two randomised controlled… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
2017
2017
BACKGROUND Combination treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators tezacaftor (VX… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2017
2017
RATIONALE In July 2015, the U.S. Food and Drug Administration approved lumacaftor/ivacaftor for use in patients with cystic… (More)
Is this relevant?
2017
2017
BACKGROUND Cystic fibrosis is an autosomal recessive disease caused by mutations in the CFTR gene that lead to progressive… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2017
2017
Safety-data for lumacaftor/ivacaftor (LUM/IVA) combination therapy in patients with severe lung disease (percent predicted forced… (More)
Is this relevant?
2017
2017
In The Lancet Respiratory Medicine, Michael Konstan and colleagues describe long-term exposure with the combination of two cystic… (More)
Is this relevant?
2016
2016
Cystic fibrosis (CF) results from mutations in the CF transmembrane conductance regulator (CFTR) gene, which codes for the CFTR… (More)
Is this relevant?
2016
2016
ORKAMBI (ivacaftor-lumacaftor [LUMA]) and KALYDECO (ivacaftor; IVA) are two new breakthrough cystic fibrosis (CF) drugs that… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2016
2016
Lumacaftor-ivacaftor (Orkambi) was recently approved by the Food and Drug Administration (FDA) in the USA to treat patients at… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic fibrosis transmembrane… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
Is this relevant?